Arkin Capital Closes Third Biotech Venture Fund at $100M
Arkin CapitalDealroom has a profile for this one. Try Dealroom → has raised $100 million for its third venture fund, strengthening its focus on early-stage biotechnology investments at a time when funding conditions across the sector remain challenging.
The new vehicle, Arkin Bio Ventures III, will target seed and Series A companies developing novel therapeutics and life sciences platforms, with a particular emphasis on programmes emerging from academic research.
The fund builds on the firm’s longstanding strategy of backing companies from inception through early clinical development.
Arkin Capital was founded in 2008 by Mori ArkinDealroom has a profile for this one. Try Dealroom →, who serves as chairman, and its venture activity is led by Pini OrbachDealroom has a profile for this one. Try Dealroom →, managing partner of Arkin Bio Ventures and Arkin Bio Capital.
The firm is known for its close collaboration with academic institutions, particularly in Israel, and for taking an active role in shaping companies at the earliest stages of their development.
Arkin Capital’s prior funds have backed companies across oncology, immunology and rare diseases, and the firm expects its third fund to continue this thematic focus while incorporating advances in areas such as computational biology and precision medicine.
With Arkin Bio Ventures III, the firm adds to its growing pool of life sciences capital and reinforces its position as a specialist investor in early-stage biotech company formation.
Sources:
Venture Capital Journal
BioXconomy
Globes
J.V.
